Post‑screen Interfaces Are The Next Big Tech Shift You Need To See Coming 
Understanding the Promise & Perils of Artificial Intelligence 
20i Launches The Web Industry’s First Unlimited Managed Hosting Assistant 
Information Security as a Core Business Responsibility 
B2BROKER Enhances B2CORE Across Web and Mobile, Advancing Its Brokerage Infrastructure Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –…
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage…
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
Acacia Quarterly Sales and Growth Table one • Total revenue for Q2 2023 was $64.6…
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
Acacia Quarterly Sales and Growth Table one • Total revenue for Q2 2023 was $64.6…
Industry First Passive Optical LAN Carbon Reduction Calculator for Enterprise Network Connectivity
Innovative carbon reduction calculator quantifies environmental impacts inside buildings and across campuses resulting from a…
Industry First Passive Optical LAN Carbon Reduction Calculator for Enterprise Network Connectivity
Innovative carbon reduction calculator quantifies environmental impacts inside buildings and across campuses resulting from a…